<DOC>
	<DOC>NCT02063295</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of beloranib in obese subjects with hypothalamic injury.</brief_summary>
	<brief_title>An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Craniopharyngioma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by BMI ≥30 and ≤60 kg/m2 Greater than 6 months posttreatment, including chemotherapy, surgery or radiation with resulting injury to the hypothalamus and/or the pituitary Stable body weight for at least 3 months Type 2 diabetes mellitus is allowed Males taking gonadotropin replacement therapy (LH/FSH) Subjects who are planning any fertility treatment within 6 months of study participation Use of weight loss agents, including herbal medications, in the past 3 months Current or anticipated chronic use of narcotics or opiates History of severe psychiatric disorders Type 1 diabetes mellitus Metabolic disorders or genetic disorders linked to obesity History of any bariatric surgery Participation in any clinical study with an investigational drug or device within the 3 months prior to enrollment in this study Blood loss or donation &gt;500 mL within the past 3 months Females who are pregnant, nursing, intend to become pregnant during the study or any males who plan to father/conceive a child within 6 months after completion of study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Beloranib</keyword>
	<keyword>ZGN-440</keyword>
	<keyword>ZGN-440 for injectable suspension</keyword>
	<keyword>ZGN-433</keyword>
</DOC>